Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

473
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
473
Coagulation01:09

Coagulation

12.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
12.4K
Coagulation01:06

Coagulation

1.7K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.7K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies.

Blood advances·2026
Same author

Repeated short-interval administration of efanesoctocog alfa is not associated with increased global coagulation potential in hemophilia A mice.

International journal of hematology·2026
Same author

Maternal-fetal transfer of emicizumab in a pregnant mouse model.

Blood advances·2026
Same author

Daily administration of long-acting adrenocorticotropic hormone (ACTH) alters the developmental pattern of plasma fibrinogen in juvenile rats.

Brain & development·2026
Same author

Physical activity patterns in people with haemophilia with and without arthropathy: a cross-sectional study using wearable sensors.

Thrombosis journal·2026

Related Experiment Video

Updated: Apr 16, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.6K

[Acquired coagulant factor inhibitors].

Keiji Nogami1

  • 1Pediatrics, Nara Medical University.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|March 14, 2015
PubMed
Summary
This summary is machine-generated.

Acquired coagulation factor inhibitors are autoimmune diseases causing bleeding. This study details the pathology and pathogenesis of factor VIII and factor V inhibitors, advancing understanding of these rare bleeding disorders.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

130

Related Experiment Videos

Last Updated: Apr 16, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.6K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

130

Area of Science:

  • Hematology
  • Immunology
  • Autoimmune Diseases

Background:

  • Acquired coagulation factor inhibitors are autoimmune diseases causing bleeding symptoms.
  • This condition differs from congenital deficiencies and is increasingly recognized, often involving anti-factor VIII autoantibodies.
  • Pathology and pathogenesis remain unclear, though immune dysregulation is suspected, particularly in the elderly.

Purpose of the Study:

  • To describe the pathology and pathogenesis of factor VIII and factor V inhibitors.
  • To enhance understanding of the coagulation process and clotting factor activation.
  • To explore potential future diagnostic and therapeutic advancements.

Main Methods:

  • Characterization of factor VIII and factor V inhibitors.
  • Analysis of the coagulation process.
  • Review of existing literature on acquired coagulation factor inhibitors.

Main Results:

  • Detailed description of the pathology and pathogenesis of factor VIII and factor V inhibitors.
  • Insights into the mechanisms of coagulation factor activation.
  • Identification of areas for future research in inhibitor analysis.

Conclusions:

  • Characterizing these inhibitors provides a deeper understanding of coagulation.
  • Further research, including new diagnostic methods, is expected to yield novel findings.
  • Elucidating inhibitory mechanisms may lead to new hemostatic treatments for acquired bleeding disorders.